bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Authors: Dmello Crismita , Sonabend Aarón , Arrieta Victor A. , Zhang Daniel Y. , Kanojia Deepak , Chen Li , Gould Andrew , Zhang Jiangshan , Kang Seong Jae , Winter Jan , Horbinski Craig , Amidei Christina , Győrffy Balázs , Cordero Alex , Chang Catalina Lee , Castro Brandyn , Hsu Patrick , Ahmed Atique U. , Lesniak Maciej S. , Stupp Roger , Sonabend Adam M.
Published: April 2023

Supplementary Table from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Supplementary Table S9 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

List of genes encoded on cytoband 19q13.42 within the significant focal regions.
Supplementary Figure from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Authors: Dmello Crismita , Sonabend Aarón , Arrieta Victor A. , Zhang Daniel Y. , Kanojia Deepak , Chen Li , Gould Andrew , Zhang Jiangshan , Kang Seong Jae , Winter Jan , Horbinski Craig , Amidei Christina , Győrffy Balázs , Cordero Alex , Chang Catalina Lee , Castro Brandyn , Hsu Patrick , Ahmed Atique U. , Lesniak Maciej S. , Stupp Roger , Sonabend Adam M.
Published: April 2023

Supplementary Figure from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Figure S5 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Correlation index of SCNA profiles before and after chemotherapy in plasma samples. Box plots and points represent the distribution of the Pearson correlation index of SCNA profiles obtained at different time points in the "therapeutic window" (see Figure 1 in the main text) with the one measured at baseline (T=0). Horizontal lines within each box indicate median values, while box whiskers are estimated as 1.5 times the standard deviations.
Supplementary Figures 1-15 from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Authors: Wang Xian , Veeraraghavan Jamunarani , Liu Chia-Chia , Cao Xixi , Qin Lanfang , Kim Jin-Ah , Tan Ying , Loo Suet Kee , Hu Yiheng , Lin Ling , Lee Sanghoon , Shea Martin J. , Mitchell Tamika , Li Shunqiang , Ellis Matthew J. , Hilsenbeck Susan G. , Schiff Rachel , Wang Xiao-Song
Published: April 2023

Supplementary Figures 1-15
Supplementary Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Authors: Skwarski Michael , McGowan Daniel R. , Belcher Elizabeth , Di Chiara Francesco , Stavroulias Dionisios , McCole Mark , Derham Jennifer L. , Chu Kwun-Ye , Teoh Eugene , Chauhan Jagat , O’Reilly Dawn , Harris Benjamin H.L. , Macklin Philip S. , Bull Joshua A. , Green Marcus , Rodriguez-Berriguete Gonzalo , Prevo Remko , Folkes Lisa K. , Campo Leticia , Ferencz Petra , Croal Paula L. , Flight Helen , Qi Cathy , Holmes Jane , O’Connor James P.B. , Gleeson Fergus V. , McKenna W. Gillies , Harris Adrian L. , Bulte Daniel , Buffa Francesca M. , Macpherson Ruth E. , Higgins Geoff S.
Published: April 2023

Supplementary Figures and Tables
Table S4 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Table S4
Supplementary Legend from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Supplementary Legend
Supplementary Data from Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker
Authors: Rickelt Steffen , Neyaz Azfar , Condon Charlene , Whittaker Charles A. , Zaidi Ali H. , Taylor Martin S. , Abbruzzese Genevieve , Mattia Anthony R. , Zukerberg Lawrence , Shroff Stuti G. , Yilmaz Omer H. , Yilmaz Osman , Wu Elizabeth Y. , Choi Won-Tak , Jobe Blair A. , Odze Robert D. , Patil Deepa T. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

Supplementary Data from Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker
Supplementary Data from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

DNA extraction from plasma, Droplet Digital PCR for HPV ctDNA Analysis, Host genome mutation and INDEL Analysis,DNA isolation from Tumor Tissue. tumor NGS,
Supplementary fig 1 from A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Authors: Yu Shengnan , Wei Shiyou , Savani Milan , Lin Xiang , Du Kuang , Mender Ilgen , Siteni Silvia , Vasilopoulos Themistoklis , Reitman Zachary J. , Ku Yin , Wu Di , Liu Hao , Tian Meng , Chen Yaohui , Labrie Marilyne , Charbonneau Casey M. , Sugarman Eric , Bowie Michelle , Hariharan Seethalakshmi , Waitkus Matthew , Jiang Wen , McLendon Roger E. , Pan Edward , Khasraw Mustafa , Walsh Kyle M. , Lu Yiling , Herlyn Meenhard , Mills Gordon , Herbig Utz , Wei Zhi , Keir Stephen T. , Flaherty Keith , Liu Lunxu , Wu Kongming , Shay Jerry W. , Abdullah Kalil , Zhang Gao , Ashley David M.
Published: April 2023

Supplementary Figure 1. (A-B) Successful labeling of CellTrace Violet for M059K and H4 cells. M059K and H4 cells were labeled with a cell membrane dye CellTrace Violet and verified the success of labeling by FACS. (C-D) Cell viability of M059K and H4 following THIO treatment. M059K and H4 cells were treated with control medium or THIO at 5µM and then determined the cell viability percentage via detecting PSVue643 and PI by FACS. (E-F) Western blot results of time-course and dose-titration experiments in M059K and H4. For the time-course experiment, cells were treated with THIO at 5µM and proteins were tested at 0, 24, 48 and 72 hours. For dose-titration experiments, cells were treated with serious doses of THIO for 72 hours. TMZ functions as control. Actin serves as a loading control.
Supplementary Table from Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data
Authors: Williamson Casey W. , Nelson Tyler J. , Thompson Caroline A. , Vitzthum Lucas K. , Zakeri Kaveh , Riviere Paul J. , Bryant Alex K. , Sharabi Andrew B. , Zou Jingjing , Mell Loren K.
Published: April 2023

Supplementary Table from Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data
Supplementary Table S1 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

Primers used in this study.
Supplementary Figure S6 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV treatments increase NK cell and T cell infiltration in the ID8-hCD47 immunocompetent ovarian cancer metastasis mouse model.
Supplementary Figure S1 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

Schematic map of OV-αCD47 used in this study.
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Authors: Liu Min , Tayob Nabihah , Penter Livius , Sellars MacLean , Tarren Anna , Chea Vipheaviny , Carulli Isabel , Huang Teddy , Li Shuqiang , Cheng Su-Chun , Le Phuong , Frackiewicz Laura , Fasse Julia , Qi Courtney , Liu Joyce F. , Stover Elizabeth H. , Curtis Jennifer , Livak Kenneth J. , Neuberg Donna , Zhang Guanglan , Matulonis Ursula A. , Wu Catherine J. , Keskin Derin B. , Konstantinopoulos Panagiotis A.
Published: April 2023

Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
Authors: Taylor Matthew H. , Betts Courtney B. , Maloney Lauren , Nadler Eric , Algazi Alain , Guarino Michael J. , Nemunaitis John , Jimeno Antonio , Patel Priti , Munugalavadla Veerendra , Tao Lin , Adkins Douglas , Goldschmidt Jerome H. , Cohen Ezra E.W. , Coussens Lisa M.
Published: April 2023

Supplementary Figure from Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
Supplementary Table from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Authors: Okada Morihito , Kato Ken , Cho Byoung Chul , Takahashi Masanobu , Lin Chen-Yuan , Chin Keisho , Kadowaki Shigenori , Ahn Myung-Ju , Hamamoto Yasuo , Doki Yuichiro , Yen Chueh-Chuan , Kubota Yutaro , Kim Sung-Bae , Hsu Chih-Hung , Holtved Eva , Xynos Ioannis , Matsumura Yasuhiro , Takazawa Akira , Kitagawa Yuko
Published: April 2023

Supplementary Table from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Supplementary Data from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Authors: Okada Morihito , Kato Ken , Cho Byoung Chul , Takahashi Masanobu , Lin Chen-Yuan , Chin Keisho , Kadowaki Shigenori , Ahn Myung-Ju , Hamamoto Yasuo , Doki Yuichiro , Yen Chueh-Chuan , Kubota Yutaro , Kim Sung-Bae , Hsu Chih-Hung , Holtved Eva , Xynos Ioannis , Matsumura Yasuhiro , Takazawa Akira , Kitagawa Yuko
Published: April 2023

Supplementary Data from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Supplementary Table S3 from Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial
Authors: Edlund Karolina , Madjar Katrin , Lebrecht Antje , Aktas Bahriye , Pilch Henryk , Hoffmann Gerald , Hofmann Manfred , Kolberg Hans-Christian , Boehm Daniel , Battista Marco , Seehase Martina , Stewen Kathrin , Gebhard Susanne , Cadenas Cristina , Marchan Rosemarie , Brenner Walburgis , Hasenburg Annette , Koelbl Heinz , Solbach Christine , Gehrmann Mathias , Tanner Berno , Weber Karsten E. , Loibl Sibylle , Sachinidis Agapios , Rahnenführer Jörg , Schmidt Marcus , Hengstler Jan G.
Published: April 2023

Classifier performance in the subgroup of ER+/HER2-patients
Supplemental Table S2 from Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial
Authors: Edlund Karolina , Madjar Katrin , Lebrecht Antje , Aktas Bahriye , Pilch Henryk , Hoffmann Gerald , Hofmann Manfred , Kolberg Hans-Christian , Boehm Daniel , Battista Marco , Seehase Martina , Stewen Kathrin , Gebhard Susanne , Cadenas Cristina , Marchan Rosemarie , Brenner Walburgis , Hasenburg Annette , Koelbl Heinz , Solbach Christine , Gehrmann Mathias , Tanner Berno , Weber Karsten E. , Loibl Sibylle , Sachinidis Agapios , Rahnenführer Jörg , Schmidt Marcus , Hengstler Jan G.
Published: April 2023

Differentially expressed genes between patients who achieved a pCR and patients who did not achieve a pCR in the EXPRESSION cohort (a), Differentially expressed genes between pathological complete and partial responders (pCR+pPR) and non-responders (pNC) in the EXPRESSION cohort (b), Gene ontology (GO) enrichment analysis of genes that were upregulated in patients with pCR (c), and Gene ontology (GO) enrichment analysis of genes that were upregulated in patients who did not achieve a pCR (d)
Table S2 from Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib
Authors: Lee Che-Jui , Schöffski Patrick , Modave Elodie , van Wezel Tom , Boeckx Bram , Sufliarsky Jozef , Gelderblom Hans , Blay Jean-Yves , Debiec-Rychter Maria , Sciot Raf , Bovée Judith V.M.G. , Lambrechts Diether , Wozniak Agnieszka
Published: April 2023

Mutational signatures in individual IMFTs and entire disease cohort.
Supplementary Figure from Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Authors: Tully Kathryn M. , Tendler Salomon , Carter Lukas M. , Sharma Sai Kiran , Samuels Zachary V. , Mandleywala Komal , Korsen Joshua A. , Delos Reyes Avelyn Mae , Piersigilli Alessandra , Travis William D. , Sen Triparna , Pillarsetty Nagavarakishore , Poirier John T. , Rudin Charles M. , Lewis Jason S.
Published: April 2023

Supplementary Figure from Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Supplementary Figure from Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
Authors: Yaddanapudi Kavitha , Stamp Bryce F. , Subrahmanyam Priyanka B. , Smolenkov Andrei , Waigel Sabine J. , Gosain Rahul , Egger Michael E. , Martin Robert C.G. , Buscaglia Robert , Maecker Holden T. , McMasters Kelly M. , Chesney Jason A.
Published: April 2023

Supplementary Figure from Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
Supplemental Table 1 and Supplemental Figure 1 from Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses
Authors: Cecil Denise L. , Liao John B. , Dang Yushe , Coveler Andrew L. , Kask Angela , Yang Yi , Childs Jennifer S. , Higgins Doreen M. , Disis Mary L.
Published: April 2023

Detailed Adverse Events and Flow diagram of patients progression through the trial .
Supplementary Table from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Authors: Xu Jihong , Wu Pei-Jung , Lai Tzung-Huei , Sharma Pratibha , Canella Alessandro , Welker Alessandra M. , Beattie Christine E. , Elder J. Brad , Easley Michelle , Lonser Russell , Jacob Naduparambil K. , Pietrzak Maciej , Timmers Cynthia M. , Lang Frederick , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Supplementary Table from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Authors: O'Sullivan Coyne Geraldine , Kummar Shivaani , Hu James , Ganjoo Kristen , Chow Warren A. , Do Khanh T. , Zlott Jennifer , Bruns Ashley , Rubinstein Lawrence , Foster Jared C. , Juwara Lamin , Meehan Robert , Piekarz Richard , Streicher Howard , Sharon Elad , Takebe Naoko , Voth Andrea Regier , Bottaro Donald , Costello Rene , Wright John J. , Doroshow James H. , Chen Alice P.
Published: April 2023

Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Authors: Mooi Jennifer , Chionh Fiona , Savas Peter , Da Gama Duarte Jessica , Chong Geoffrey , Brown Stephen , Wong Rachel , Price Timothy J. , Wann Alysson , Skrinos Effie , Mariadason John M. , Tebbutt Niall C.
Published: April 2023

Supplementary tables 1-3
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Authors: Bychkovsky Brittany L. , Li Tianyu , Sotelo Jilliane , Tayob Nabihah , Mercado Joanna , Gomy Israel , Chittenden Anu , Kane Sarah , Stokes Samantha , Hughes Melissa E. , Kim Ji Seok , Umeton Renato , Awad Mark M. , Konstantinopoulos Panagiotis A. , Yurgelun Matthew B. , Wolpin Brian M. , Taplin Mary-Ellen , Newmark Randall E. , Johnson Bruce E. , Lindeman Neal I. , MacConaill Laura E. , Garber Judy E. , Lin Nancy U.
Published: April 2023

Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Authors: Mooi Jennifer , Chionh Fiona , Savas Peter , Da Gama Duarte Jessica , Chong Geoffrey , Brown Stephen , Wong Rachel , Price Timothy J. , Wann Alysson , Skrinos Effie , Mariadason John M. , Tebbutt Niall C.
Published: April 2023

Supplementary Legend
Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Authors: Bychkovsky Brittany L. , Li Tianyu , Sotelo Jilliane , Tayob Nabihah , Mercado Joanna , Gomy Israel , Chittenden Anu , Kane Sarah , Stokes Samantha , Hughes Melissa E. , Kim Ji Seok , Umeton Renato , Awad Mark M. , Konstantinopoulos Panagiotis A. , Yurgelun Matthew B. , Wolpin Brian M. , Taplin Mary-Ellen , Newmark Randall E. , Johnson Bruce E. , Lindeman Neal I. , MacConaill Laura E. , Garber Judy E. , Lin Nancy U.
Published: April 2023

Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Data from DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Authors: Venugopal Kartika , Feng Yang , Nowialis Pawel , Xu Huanzhou , Shabashvili Daniil E. , Berntsen Cassandra M. , Kaur Prabhjot , Krajcik Kathryn I. , Taragjini Christina , Zaroogian Zachary , Casellas Román Heidi L. , Posada Luisa M. , Gunaratne Chamara , Li Jianping , Dupéré-Richer Daphné , Bennett Richard L. , Pondugula Santhi , Riva Alberto , Cogle Christopher R. , Opavsky Rene , Law Brian K. , Bhaduri-McIntosh Sumita , Kubicek Stefan , Staber Philipp B. , Licht Jonathan D. , Bird Jonathan E. , Guryanova Olga A.
Published: April 2023

Supplementary Data from DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Supplementary Data from Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Authors: Terry Stéphane , Dalban Cécile , Rioux-Leclercq Nathalie , Adam Julien , Meylan Maxime , Buart Stéphanie , Bougoüin Antoine , Lespagnol Alexandra , Dugay Frédéric , Moreno Irelka Colina , Lacroix Guillaume , Lorens James B. , Gausdal Gro , Fridman Wolf H. , Mami-Chouaib Fathia , Chaput Nathalie , Beuselinck Benoit , Chabaud Sylvie , Barros-Monteiro Janice , Vano Yann , Escudier Bernard , Sautès-Fridman Catherine , Albiges Laurence , Chouaib Salem
Published: April 2023

This file contains 6 supplementary figures and 5 supplementary Tables. Supplementary Figure S1 - Protein expression pattern of AXL in ccRCC specimens. Supplementary Figure S2 - Response rates, Survival and Biomarker analyses according to AXLneg, AXLlow and AXLhigh expression Supplementary Figure S3 - ORR and Progression-Free Survival according to PD-L1 Status alone or by grouping AXL expression plus PD-L1 status Supplementary Figure S4 - High AXL expression plus PD-L1 TC positivity is associated with worse OS in Nivolumab-treated patients in IMDC intermediate-risk/poor-risk group Supplementary Figure S5 - VHL status does not interfere with outcomes or AXL expression upon treatment with Nivolumab Supplementary Figure S6 - Biomarker distribution across AXL groups stratified based on VHL status
Supplementary Figure from CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Authors: Kumar Anupam , Mohamed Esraa , Tong Schuyler , Chen Katharine , Mukherjee Joydeep , Lim Yunita , Wong Cynthia M. , Boosalis Zoe , Shai Anny , Pieper Russell O. , Gupta Nalin , Perry Arie , Bollen Andrew W. , Molinaro Annette M. , Solomon David A. , Shieh Joseph T.C. , Phillips Joanna J.
Published: April 2023

Supplementary Figure from CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Supplementary Data from CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Authors: Kumar Anupam , Mohamed Esraa , Tong Schuyler , Chen Katharine , Mukherjee Joydeep , Lim Yunita , Wong Cynthia M. , Boosalis Zoe , Shai Anny , Pieper Russell O. , Gupta Nalin , Perry Arie , Bollen Andrew W. , Molinaro Annette M. , Solomon David A. , Shieh Joseph T.C. , Phillips Joanna J.
Published: April 2023

Supplementary Data from CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Supplementary Data from Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
Authors: Oehl Kathrin , Vrugt Bart , Wagner Ulrich , Kirschner Michaela B. , Meerang Mayura , Weder Walter , Felley-Bosco Emanuela , Wollscheid Bernd , Bankov Katrin , Demes Melanie C. , Opitz Isabelle , Wild Peter J.
Published: April 2023

Suppl Figures, Tables, Methods
Supplementary Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Authors: Wu Xiaohua , Zhu Jianqing , Wang Jing , Lin Zhongqiu , Yin Rutie , Sun Wei , Zhou Qi , Zhang Songling , Wang Danbo , Shi Hong , Gao Yunong , Huang Yi , Li Guiling , Wang Xiuli , Cheng Ying , Lou Ge , Gao Qinglei , Wang Li , Du Xiuping , Pan Mei , Mu Xiyan , Li Li , Li Miao , Mu Song , Kong Beihua
Published: April 2023

Supplementary Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Authors: Lee Jessica K. , Hazar-Rethinam Mehlika , Decker Brennan , Gjoerup Ole , Madison Russell W. , Lieber Daniel S. , Chung Jon H. , Schrock Alexa B. , Creeden James , Venstrom Jeffrey , Alexander Brian , Oxnard Geoffrey R.
Published: April 2023

Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Date from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Authors: Luginbuhl Adam J. , Johnson Jennifer M. , Harshyne Larry A. , Linnenbach Alban J. , Shukla Sanket K. , Alnemri Angela , Kumar Gaurav , Cognetti David M. , Curry Joseph M. , Kotlov Nikita , Antysheva Zoya , Degryse Sandrine , Mannion Kyle , Gibson Michael K. , Netterville James , Brown Brandee , Axelrod Rita , Zinner Ralph , Tuluc Madalina , Gargano Stacey , Leiby Benjamin E. , Shimada Ayako , Mahoney My G. , Martinez-Outschoorn Ubaldo , Rodeck Ulrich , Kim Young J. , South Andrew P. , Argiris Athanassios
Published: April 2023

Supplementary Date from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Supplementary Table S9 from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Supplementary Table S9. The correlation analysis between ERBB2/ERBB3 and EMT score in SPORE 442 KRASG12C lung cancer mutants.
Supplementary Table S8 from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Supplementary Table S8. The TGFβ-EMT analysis of 8 KRASG12C lung cancer cell lines.
Supplementary Figure from A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
Authors: Dylgjeri Emanuela , Kothari Vishal , Shafi Ayesha A. , Semenova Galina , Gallagher Peter T. , Guan Yi F. , Pang Angel , Goodwin Jonathan F. , Irani Swati , McCann Jennifer J. , Mandigo Amy C. , Chand Saswati , McNair Christopher M. , Vasilevskaya Irina , Schiewer Matthew J. , Lallas Costas D. , McCue Peter A. , Gomella Leonard G. , Seifert Erin L. , Carroll Jason S. , Butler Lisa M. , Holst Jeff , Kelly William K. , Knudsen Karen E.
Published: April 2023

Supplementary Figure from A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
Supplementary Table from cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Authors: Li Shuo , Zeng Weihua , Ni Xiaohui , Zhou Yonggang , Stackpole Mary L. , Noor Zorawar S. , Yuan Zuyang , Neal Adam , Memarzadeh Sanaz , Garon Edward B. , Dubinett Steven M. , Li Wenyuan , Zhou Xianghong Jasmine
Published: April 2023

Supplementary Table from cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Supplementary Figure from cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Authors: Li Shuo , Zeng Weihua , Ni Xiaohui , Zhou Yonggang , Stackpole Mary L. , Noor Zorawar S. , Yuan Zuyang , Neal Adam , Memarzadeh Sanaz , Garon Edward B. , Dubinett Steven M. , Li Wenyuan , Zhou Xianghong Jasmine
Published: April 2023

Supplementary Figure from cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Figure_S3 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Authors: Westin Shannon N. , Labrie Marilyne , Litton Jennifer K. , Blucher Aurora , Fang Yong , Vellano Christopher P. , Marszalek Joseph R. , Feng Ningping , Ma XiaoYan , Creason Allison , Fellman Bryan , Yuan Ying , Lee Sanghoon , Kim Tae-Beom , Liu Jinsong , Chelariu-Raicu Anca , Chen Tsun Hsuan , Kabil Nashwa , Soliman Pamela T. , Frumovitz Michael , Schmeler Katheleen M. , Jazaeri Amir , Lu Karen H. , Murthy Rashmi , Meyer Larissa A. , Sun Charlotte C. , Sood Anil K. , Coleman Robert L. , Mills Gordon B.
Published: April 2023

Supplementary Figure S3
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Authors: Zhao Ning , Chopra Shalini , Trepka Kai , Wang Yung-Hua , Sakhamuri Sasank , Hooshdaran Nima , Kim Hyunjung , Zhou Jie , Lim Shion A. , Leung Kevin K. , Egusa Emily A. , Zhu Jun , Zhang Li , Foye Adam , Sriram Renuka , Chan Emily , Seo Youngho , Feng Felix Y. , Small Eric J. , Chou Jonathan , Wells James A. , Aggarwal Rahul , Evans Michael J.
Published: April 2023

Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
Authors: Fitzpatrick Amanda , Iravani Marjan , Mills Adam , Childs Lucy , Alaguthurai Thanussuyah , Clifford Angela , Garcia-Murillas Isaac , Van Laere Steven , Dirix Luc , Harries Mark , Okines Alicia , Turner Nicholas C. , Haider Syed , Tutt Andrew N.J. , Isacke Clare M.
Published: April 2023

Supplementary Figure from Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
Supplementary Data from Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
Authors: Fitzpatrick Amanda , Iravani Marjan , Mills Adam , Childs Lucy , Alaguthurai Thanussuyah , Clifford Angela , Garcia-Murillas Isaac , Van Laere Steven , Dirix Luc , Harries Mark , Okines Alicia , Turner Nicholas C. , Haider Syed , Tutt Andrew N.J. , Isacke Clare M.
Published: April 2023

Supplementary Data from Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
Supplementary Table from FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Chen Youhao , Xie Wen , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhuang Wei , Liu Shu , Huang Min , Wang Xueding , Zhang Li
Published: April 2023

Supplementary Table from FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Supplementary Figure from FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Chen Youhao , Xie Wen , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhuang Wei , Liu Shu , Huang Min , Wang Xueding , Zhang Li
Published: April 2023

Supplementary Figure from FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Authors: Diorio Caroline , Shraim Rawan , Myers Regina , Behrens Edward M. , Canna Scott , Bassiri Hamid , Aplenc Richard , Burudpakdee Chakkapong , Chen Fang , DiNofia Amanda M. , Gill Saar , Gonzalez Vanessa , Lambert Michele P. , Leahy Allison Barz , Levine Bruce L. , Lindell Robert B. , Maude Shannon L. , Melenhorst J. Joseph , Newman Haley , Perazzelli Jessica , Seif Alix E. , Lacey Simon F. , June Carl H. , Barrett David M. , Grupp Stephan A. , Teachey David T.
Published: April 2023

Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Authors: Noh Joseph J. , Cho Young-Jae , Ryu Ji-Yoon , Choi Jung-Joo , Hwang Jae Ryoung , Choi Ju-Yeon , Lee Jeong-Won
Published: April 2023

Supplementary Figure from Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Supplementary Figure from First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes
Authors: Pal Rahul , Hom Marisa E. , van den Berg Nynke S. , Lwin Thinzar M. , Lee Yu-Jin , Prilutskiy Andrey , Faquin William , Yang Eric , Saladi Srinivas V. , Varvares Mark A. , Rosenthal Eben L. , Kumar Anand T.N.
Published: April 2023

Supplementary Figure from First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes
Supplementary Data from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Authors: Diorio Caroline , Shraim Rawan , Myers Regina , Behrens Edward M. , Canna Scott , Bassiri Hamid , Aplenc Richard , Burudpakdee Chakkapong , Chen Fang , DiNofia Amanda M. , Gill Saar , Gonzalez Vanessa , Lambert Michele P. , Leahy Allison Barz , Levine Bruce L. , Lindell Robert B. , Maude Shannon L. , Melenhorst J. Joseph , Newman Haley , Perazzelli Jessica , Seif Alix E. , Lacey Simon F. , June Carl H. , Barrett David M. , Grupp Stephan A. , Teachey David T.
Published: April 2023

Supplementary Data from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Authors: Cristescu Razvan , Nebozhyn Michael , Zhang Chunsheng , Albright Andrew , Kobie Julie , Huang Lingkang , Zhao Qing , Wang Anran , Ma Hua , Alexander Cao Z. , Morrissey Michael , Ribas Antoni , Grivas Petros , Cescon David W. , McClanahan Terrill K. , Snyder Alexandra , Ayers Mark , Lunceford Jared , Loboda Andrey
Published: April 2023

Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Table from Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Authors: Denize Thomas , Farah Subrina , Cimadamore Alessia , Flaifel Abdallah , Walton Emily , Sticco-Ivins Maura A. , Labaki Chris , Braun David A. , Sun Maxine , Wang Evelyn , Xie Wanling , Choueiri Toni K. , Signoretti Sabina
Published: April 2023

Supplementary Table from Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Authors: Cristescu Razvan , Nebozhyn Michael , Zhang Chunsheng , Albright Andrew , Kobie Julie , Huang Lingkang , Zhao Qing , Wang Anran , Ma Hua , Alexander Cao Z. , Morrissey Michael , Ribas Antoni , Grivas Petros , Cescon David W. , McClanahan Terrill K. , Snyder Alexandra , Ayers Mark , Lunceford Jared , Loboda Andrey
Published: April 2023

Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Data from Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Authors: Pollyea Daniel A. , DiNardo Courtney D. , Arellano Martha L. , Pigneux Arnaud , Fiedler Walter , Konopleva Marina , Rizzieri David A. , Smith B. Douglas , Shinagawa Atsushi , Lemoli Roberto M. , Dail Monique , Duan Yinghui , Chyla Brenda , Potluri Jalaja , Miller Catherine L. , Kantarjian Hagop M.
Published: April 2023

Supplementary Data from Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Authors: Leddon Jennifer L. , Gulati Shuchi , Haque Sulsal , Allen Casey , Palackdharry Sarah , Mathews Maria , Kurtzweil Nicky , Riaz Muhammed Kashif , Takiar Vinita , Nagasaka Misako , Patil Yash , Zender Chad , Tang Alice , Cervenka Brian , McGrath Julie , Korn W. Michael , Hinrichs Benjamin H. , Jandarov Roman , Harun Nusrat , Sukari Ammar , Wise-Draper Trisha M.
Published: April 2023

Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Supplementary Table from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Authors: Batalini Felipe , Xiong Niya , Tayob Nabihah , Polak Madeline , Eismann Julia , Cantley Lewis C. , Shapiro Geoffrey I. , Adalsteinsson Viktor , Winer Eric P. , Konstantinopoulos Panagiotis A. , D'Andrea Alan , Swisher Elizabeth M. , Matulonis Ursula A. , Wulf Gerburg M. , Mayer Erica L.
Published: April 2023

Supplementary Table from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Supplementary Figure from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Authors: Leddon Jennifer L. , Gulati Shuchi , Haque Sulsal , Allen Casey , Palackdharry Sarah , Mathews Maria , Kurtzweil Nicky , Riaz Muhammed Kashif , Takiar Vinita , Nagasaka Misako , Patil Yash , Zender Chad , Tang Alice , Cervenka Brian , McGrath Julie , Korn W. Michael , Hinrichs Benjamin H. , Jandarov Roman , Harun Nusrat , Sukari Ammar , Wise-Draper Trisha M.
Published: April 2023

Supplementary Figure from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Authors: Batalini Felipe , Xiong Niya , Tayob Nabihah , Polak Madeline , Eismann Julia , Cantley Lewis C. , Shapiro Geoffrey I. , Adalsteinsson Viktor , Winer Eric P. , Konstantinopoulos Panagiotis A. , D'Andrea Alan , Swisher Elizabeth M. , Matulonis Ursula A. , Wulf Gerburg M. , Mayer Erica L.
Published: April 2023

Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Supplementary Figure from Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Authors: Shi Qiong , Liu Lin , Chen Jianru , Zhang Weigang , Guo Weinan , Wang Xiao , Wang Huina , Guo Sen , Yue Qiao , Ma Jingjing , Liu Yu , Zhu Guannan , Zhao Tao , Zhao Jianhong , Liu Ying , Gao Tianwen , Li Chunying
Published: April 2023

Supplementary Figure from Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Supplementary Figure from Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
Authors: Kline Cassie , Jain Payal , Kilburn Lindsay , Bonner Erin R. , Gupta Nalin , Crawford John R. , Banerjee Anu , Packer Roger J. , Villanueva-Meyer Javier , Luks Tracy , Zhang Yalan , Kambhampati Madhuri , Zhang Jie , Yadavilli Sridevi , Zhang Bo , Gaonkar Krutika S. , Rokita Jo Lynne , Kraya Adam , Kuhn John , Liang Winnie , Byron Sara , Berens Michael , Molinaro Annette , Prados Michael , Resnick Adam , Waszak Sebastian M. , Nazarian Javad , Mueller Sabine
Published: April 2023

Supplementary Figure from Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Authors: Wagner Michael J. , Zhang Yuzheng , Cranmer Lee D. , Loggers Elizabeth T. , Black Graeme , McDonnell Sabrina , Maxwell Shannon , Johnson Rylee , Moore Roxanne , Hermida de Viveiros Pedro , Aicher Lauri , Smythe Kimberly S. , He Qianchuan , Jones Robin L. , Pollack Seth M.
Published: April 2023

Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Supplementary Data from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Authors: Wagner Michael J. , Zhang Yuzheng , Cranmer Lee D. , Loggers Elizabeth T. , Black Graeme , McDonnell Sabrina , Maxwell Shannon , Johnson Rylee , Moore Roxanne , Hermida de Viveiros Pedro , Aicher Lauri , Smythe Kimberly S. , He Qianchuan , Jones Robin L. , Pollack Seth M.
Published: April 2023

Supplementary Data from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Supplementary Data from Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Authors: Shi Qiong , Liu Lin , Chen Jianru , Zhang Weigang , Guo Weinan , Wang Xiao , Wang Huina , Guo Sen , Yue Qiao , Ma Jingjing , Liu Yu , Zhu Guannan , Zhao Tao , Zhao Jianhong , Liu Ying , Gao Tianwen , Li Chunying
Published: April 2023

Supplementary Data from Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Authors: Hussain Maha , Corcoran Claire , Sibilla Caroline , Fizazi Karim , Saad Fred , Shore Neal , Sandhu Shahneen , Mateo Joaquin , Olmos David , Mehra Niven , Kolinsky Michael P. , Roubaud Guilhem , Özgüroǧlu Mustafa , Matsubara Nobuaki , Gedye Craig , Choi Young Deuk , Padua Charles , Kohlmann Alexander , Huisden Robert , Elvin Julia A. , Kang Jinyu , Adelman Carrie A. , Allen Allison , Poehlein Christian , de Bono Johann
Published: April 2023

Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Wise-Draper Trisha M. , Gulati Shuchi , Palackdharry Sarah , Hinrichs Benjamin H. , Worden Francis P. , Old Matthew O. , Dunlap Neal E. , Kaczmar John M. , Patil Yash , Riaz Muhammed Kashif , Tang Alice , Mark Jonathan , Zender Chad , Gillenwater Ann M. , Bell Diana , Kurtzweil Nicky , Mathews Maria , Allen Casey L. , Mierzwa Michelle L. , Casper Keith , Jandarov Roman , Medvedovic Mario , Lee J. Jack , Harun Nusrat , Takiar Vinita , Gillison Maura
Published: April 2023

Supplementary Figure from Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Authors: Li Jian , Cai Shirong , Zhou Yongjian , Zhang Jun , Zhou Ye , Cao Hui , Wu Xin , Deng Yanhong , Huang Zhao , Dong Juan , Shen Lin
Published: April 2023

Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Supplementary Figure from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Authors: Denize Thomas , Hou Yue , Pignon Jean-Christophe , Walton Emily , West Destiny J. , Freeman Gordon J. , Braun David A. , Wu Catherine J. , Gupta Saurabh , Motzer Robert J. , Atkins Michael B. , McDermott David , Choueiri Toni K. , Shukla Sachet A. , Signoretti Sabina
Published: April 2023

Supplementary Figure from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Supplementary Table from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Authors: Foldi Julia , Kahn Adriana , Silber Andrea , Qing Tao , Reisenbichler Emily , Fischbach Neal , Persico Justin , Adelson Kerin , Katoch Anamika , Chagpar Anees , Park Tristen , Blanchard Adam , Blenman Kim , Rimm David L. , Pusztai Lajos
Published: April 2023

Supplementary Table from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Supplementary Table from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Authors: Brashears Caitlyn B. , Prudner Bethany C. , Rathore Richa , Caldwell Katharine E. , Dehner Carina A. , Buchanan Jane L. , Lange Sara E.S. , Poulin Neal , Sehn Jennifer K. , Roszik Jason , Spitzer Dirk , Jones Kevin B. , O'Keefe Regis , Nielsen Torsten O. , Taylor Eric B. , Held Jason M. , Hawkins William , Van Tine Brian A.
Published: April 2023

Supplementary Table from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Supplementary Figure from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Authors: Brashears Caitlyn B. , Prudner Bethany C. , Rathore Richa , Caldwell Katharine E. , Dehner Carina A. , Buchanan Jane L. , Lange Sara E.S. , Poulin Neal , Sehn Jennifer K. , Roszik Jason , Spitzer Dirk , Jones Kevin B. , O'Keefe Regis , Nielsen Torsten O. , Taylor Eric B. , Held Jason M. , Hawkins William , Van Tine Brian A.
Published: April 2023

Supplementary Figure from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102